Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in Advanced Mycosis Fungoides
NCT05538988Phase 2Withdrawn
- Sponsor
- American Health Staffing Group
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in mycosis fungoides (MF), sponsored by American Health Staffing Group. Primary endpoint: Objective Response Rate. Planned start Dec 2024; status: withdrawn.
02
Drugs
cemiplimab
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT05538988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538988.